Listed

Phio Pharmaceuticals Corp.: Form 10-K for the period ended Dec 31, 2015

Filed with the SEC on Mar 30, 2016 and accepted by EDGAR at Mar 30, 2016, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2015-01-01 to 2015-12-31$6.9mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2015-01-01 to 2015-12-31−$10.2mus-gaap:OperatingIncomeLoss
Income tax12 months2015-01-01 to 2015-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2015-01-01 to 2015-12-31−$10.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2015-01-01 to 2015-12-31−$0.21us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2015-01-01 to 2015-12-31−$7.3mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure12 months2015-01-01 to 2015-12-31$57.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-12-31$5.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-12-31$11.0mus-gaap:AssetsCurrent
Total assetsAt period end2015-12-31$11.2mus-gaap:Assets
Current liabilitiesAt period end2015-12-31$2.3mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2015-12-31$8.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-16-523721. Last ingested by Listed: Nov 12, 2026, 20:44 ET. Listed shows no prices and gives no investment advice.